Innovations in GLP-1 Receptor Agonist Therapy: Patient-Centered Strategies to Overcome Barriers and Reduce Cardiometabolic Risk Evaluation (ID: i738a)

Question Title

* 1. Following your participation in this activity, how confident are you in the management of patients with T2DM in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 2. How committed are you to making changes in your practice based on your participation in this activity?

Very committed

Committed

Neutral

Not committed

I do not plan to make changes

Question Title

* 3. What is your degree?

MD/DO

Other (please specify)

Question Title

* 4. How many patients with diabetes do you currently manage in your practice? Please respond with your best appropriate number.

Question Title

* 5. How many years have you been in practice?

≥1

1-10

11-20

≥21

Question Title

* 6. As a result of participating in this activity, will you change components of your communication with patients with T2DM?

Yes

If yes, please explain.

Question Title

* 7. Which of the following best describes the impact of this activity on your performance?

I gained new strategies/skills/information that I can apply to my area of practice

I need more information before I change my practice behavior

This activity will not change my practice, as my current practice is consistent with the information presented

This activity will not change my practice, as I do not agree with the information presented

Question Title

* 8. After participating in today’s activity, I am now able to:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Explain geographic trends in access to endocrinologists and define the critical role of PCPs in the management of T2DM	Explain geographic trends in access to endocrinologists and define the critical role of PCPs in the management of T2DM Strongly agree	Explain geographic trends in access to endocrinologists and define the critical role of PCPs in the management of T2DM Agree	Explain geographic trends in access to endocrinologists and define the critical role of PCPs in the management of T2DM Neutral	Explain geographic trends in access to endocrinologists and define the critical role of PCPs in the management of T2DM Disagree	Explain geographic trends in access to endocrinologists and define the critical role of PCPs in the management of T2DM Strongly disagree
Compare the underlying pathophysiological mechanisms and pharmacokinetic/pharmacodynamic profiles for currently available and emerging GLP-1 RA agents	Compare the underlying pathophysiological mechanisms and pharmacokinetic/pharmacodynamic profiles for currently available and emerging GLP-1 RA agents Strongly agree	Compare the underlying pathophysiological mechanisms and pharmacokinetic/pharmacodynamic profiles for currently available and emerging GLP-1 RA agents Agree	Compare the underlying pathophysiological mechanisms and pharmacokinetic/pharmacodynamic profiles for currently available and emerging GLP-1 RA agents Neutral	Compare the underlying pathophysiological mechanisms and pharmacokinetic/pharmacodynamic profiles for currently available and emerging GLP-1 RA agents Disagree	Compare the underlying pathophysiological mechanisms and pharmacokinetic/pharmacodynamic profiles for currently available and emerging GLP-1 RA agents Strongly disagree
Evaluate updated guideline recommendations and the clinical trial data on the efficacy and safety of specific GLP-1 RAs, in addition to recent CVOT, patient satisfaction, and adherence data	Evaluate updated guideline recommendations and the clinical trial data on the efficacy and safety of specific GLP-1 RAs, in addition to recent CVOT, patient satisfaction, and adherence data Strongly agree	Evaluate updated guideline recommendations and the clinical trial data on the efficacy and safety of specific GLP-1 RAs, in addition to recent CVOT, patient satisfaction, and adherence data Agree	Evaluate updated guideline recommendations and the clinical trial data on the efficacy and safety of specific GLP-1 RAs, in addition to recent CVOT, patient satisfaction, and adherence data Neutral	Evaluate updated guideline recommendations and the clinical trial data on the efficacy and safety of specific GLP-1 RAs, in addition to recent CVOT, patient satisfaction, and adherence data Disagree	Evaluate updated guideline recommendations and the clinical trial data on the efficacy and safety of specific GLP-1 RAs, in addition to recent CVOT, patient satisfaction, and adherence data Strongly disagree
Identify common provider-and patient-related barriers so that GLP-1 RAs can be introduced to more effectively control glucose, improve cardiometabolic risk factors, and increase patient satisfaction and adherence	Identify common provider-and patient-related barriers so that GLP-1 RAs can be introduced to more effectively control glucose, improve cardiometabolic risk factors, and increase patient satisfaction and adherence Strongly agree	Identify common provider-and patient-related barriers so that GLP-1 RAs can be introduced to more effectively control glucose, improve cardiometabolic risk factors, and increase patient satisfaction and adherence Agree	Identify common provider-and patient-related barriers so that GLP-1 RAs can be introduced to more effectively control glucose, improve cardiometabolic risk factors, and increase patient satisfaction and adherence Neutral	Identify common provider-and patient-related barriers so that GLP-1 RAs can be introduced to more effectively control glucose, improve cardiometabolic risk factors, and increase patient satisfaction and adherence Disagree	Identify common provider-and patient-related barriers so that GLP-1 RAs can be introduced to more effectively control glucose, improve cardiometabolic risk factors, and increase patient satisfaction and adherence Strongly disagree
Describe the optimal use of GLP-1 RAs in the context of practice-based clinical scenarios	Describe the optimal use of GLP-1 RAs in the context of practice-based clinical scenarios Strongly agree	Describe the optimal use of GLP-1 RAs in the context of practice-based clinical scenarios Agree	Describe the optimal use of GLP-1 RAs in the context of practice-based clinical scenarios Neutral	Describe the optimal use of GLP-1 RAs in the context of practice-based clinical scenarios Disagree	Describe the optimal use of GLP-1 RAs in the context of practice-based clinical scenarios Strongly disagree

Question Title

* 9. Vivian A. Fonseca, MD, FRCP, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 10. Richard E. Pratley, MD, effectively:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Presented the material	Presented the material Strongly agree	Presented the material Agree	Presented the material Neutral	Presented the material Disagree	Presented the material Strongly disagree
Avoided commercial bias	Avoided commercial bias Strongly agree	Avoided commercial bias Agree	Avoided commercial bias Neutral	Avoided commercial bias Disagree	Avoided commercial bias Strongly disagree

Question Title

* 11. The content presented:

	Strongly agree	Agree	Neutral	Disagree	Strongly disagree
Enhanced my current knowledge base	Enhanced my current knowledge base Strongly agree	Enhanced my current knowledge base Agree	Enhanced my current knowledge base Neutral	Enhanced my current knowledge base Disagree	Enhanced my current knowledge base Strongly disagree
Addressed my most pressing questions	Addressed my most pressing questions Strongly agree	Addressed my most pressing questions Agree	Addressed my most pressing questions Neutral	Addressed my most pressing questions Disagree	Addressed my most pressing questions Strongly disagree
Promoted improvements or quality in health care	Promoted improvements or quality in health care Strongly agree	Promoted improvements or quality in health care Agree	Promoted improvements or quality in health care Neutral	Promoted improvements or quality in health care Disagree	Promoted improvements or quality in health care Strongly disagree
Was scientifically rigorous and evidence based	Was scientifically rigorous and evidence based Strongly agree	Was scientifically rigorous and evidence based Agree	Was scientifically rigorous and evidence based Neutral	Was scientifically rigorous and evidence based Disagree	Was scientifically rigorous and evidence based Strongly disagree

Question Title

* 12. What barriers do you see to making changes in your practice?

Question Title

* 13. Please list any clinical issues/problems within your scope of practice that you would like to see addressed in future educational activities:

Question Title

* 14. If you indicated that you perceived commercial bias or influence, please describe:

Question Title

* 15. Additional Education: If you would like to participate in a text-message based Mobile Coach activity related to the content of this program, please provide your name and mobile number below, or text “Hi Aaron” to 505-357-1236.

What can Mobile Coach do for you?

Remind you of key content learned in this activity

Help set goals for your week and weeks to come

Challenge you with interactive questions

Provide practical advice to implement content learned into practice

Following enrollment, participants will receive 1-3 text messages a week, at varied times, for a period of 8 weeks.

**Disclaimer: This is not mandatory and you may opt out at any time. Information we collect will be used for educational purposes only and will not be shared.*

Yes, I would like to participate in the text-based Mobile Coach activity.

First and Last Name:
Mobile Phone: